Different types of targeted drugs have been tested in clinical trials for NPC, including monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) as well as small-molecule tyrosine kinase inhibitors (TKIs) [5-7]. Here, VEGFA is linked to nasopharyngeal carcinoma.